As the global population ages, demand is increasing for improved treatments in pain management, neurodegenerative and cerebrovascular diseases. Since the “Decade of the Brain” in the 1990s, many new drugs are now progressing through clinical studies (more than 500 to treat neurological disorders at the last count).
Kendle’s expert CNS team has unsurpassed experience in Phase I-IV clinical trials; they’re ready to help you meet your expanding neurological business objectives.